These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 38846976)

  • 1. Circulating tumour DNA detects somatic variants contributing to spatial and temporal intra-tumoural heterogeneity in head and neck squamous cell carcinoma.
    Payne KFB; Brotherwood P; Suriyanarayanan H; Brooks JM; Batis N; Beggs AD; Gendoo DMA; Mehanna H; Nankivell P
    Front Oncol; 2024; 14():1374816. PubMed ID: 38846976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liquid BIOpsy for MiNimal RESidual DiSease Detection in Head and Neck Squamous Cell Carcinoma (LIONESS)-a personalised circulating tumour DNA analysis in head and neck squamous cell carcinoma.
    Flach S; Howarth K; Hackinger S; Pipinikas C; Ellis P; McLay K; Marsico G; Forshew T; Walz C; Reichel CA; Gires O; Canis M; Baumeister P
    Br J Cancer; 2022 May; 126(8):1186-1195. PubMed ID: 35132238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating tumour DNA alterations: emerging biomarker in head and neck squamous cell carcinoma.
    Huang X; Duijf PHG; Sriram S; Perera G; Vasani S; Kenny L; Leo P; Punyadeera C
    J Biomed Sci; 2023 Aug; 30(1):65. PubMed ID: 37559138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dynamics of cell-free tumour DNA correlate with treatment response of head and neck cancer patients receiving radiochemotherapy.
    Hilke FJ; Muyas F; Admard J; Kootz B; Nann D; Welz S; Rieß O; Zips D; Ossowski S; Schroeder C; Clasen K
    Radiother Oncol; 2020 Oct; 151():182-189. PubMed ID: 32687856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Prognostic and Therapeutic Value of the Mutational Profile of Blood and Tumor Tissue in Head and Neck Squamous Cell Carcinoma.
    Wilson HL; D'Agostino RB; Meegalla N; Petro R; Commander S; Topaloglu U; Zhang W; Porosnicu M
    Oncologist; 2021 Feb; 26(2):e279-e289. PubMed ID: 33098199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating tumour DNA kinetics in recurrent/metastatic head and neck squamous cell cancer patients.
    Taylor K; Zou J; Magalhaes M; Oliva M; Spreafico A; Hansen AR; McDade SS; Coyle VM; Lawler M; Elimova E; Bratman SV; Siu LL
    Eur J Cancer; 2023 Jul; 188():29-38. PubMed ID: 37182343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison between mutational profiles in tumour tissue DNA and circulating tumour DNA in head and neck squamous cell carcinoma - A systematic review.
    Huang X; Leo P; Jones L; Duijf PHG; Hartel G; Kenny L; Vasani S; Punyadeera C
    Mutat Res Rev Mutat Res; 2024; 793():108477. PubMed ID: 37977279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Next-generation sequencing (NGS) profiling of matched tumor and circulating tumor DNA (ctDNA) in head and neck squamous cell carcinoma (HNSCC).
    Economopoulou P; Spathis A; Kotsantis I; Maratou E; Anastasiou M; Moutafi MK; Kirkasiadou M; Pantazopoulos A; Giannakakou M; Edelstein DL; Sloane H; Fredebohm J; Jones FS; Kyriazoglou A; Gavrielatou N; Foukas P; Panayiotides I; Psyrri A
    Oral Oncol; 2023 Apr; 139():106358. PubMed ID: 36871349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liquid biopsy for mutational profiling of locoregional recurrent and/or metastatic head and neck squamous cell carcinoma.
    Galot R; van Marcke C; Helaers R; Mendola A; Goebbels RM; Caignet X; Ambroise J; Wittouck K; Vikkula M; Limaye N; Machiels JH
    Oral Oncol; 2020 May; 104():104631. PubMed ID: 32169746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor-Naïve Multimodal Profiling of Circulating Tumor DNA in Head and Neck Squamous Cell Carcinoma.
    Burgener JM; Zou J; Zhao Z; Zheng Y; Shen SY; Huang SH; Keshavarzi S; Xu W; Liu FF; Liu G; Waldron JN; Weinreb I; Spreafico A; Siu LL; de Almeida JR; Goldstein DP; Hoffman MM; De Carvalho DD; Bratman SV
    Clin Cancer Res; 2021 Aug; 27(15):4230-4244. PubMed ID: 34158359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of genetic variants of frequently mutated genes in human papillomavirus-negative primary head and neck squamous cell carcinoma, resection margins, local recurrences and corresponding circulating cell-free DNA.
    Flach S; Kumbrink J; Walz C; Hess J; Drexler G; Belka C; Canis M; Jung A; Baumeister P
    J Oral Pathol Med; 2022 Sep; 51(8):738-746. PubMed ID: 35895622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating Tumor DNA in Head and Neck Squamous Cell Carcinoma: Association with Metabolic Tumor Burden Determined with FDG-PET/CT.
    Silvoniemi A; Laine J; Aro K; Nissi L; Bäck L; Schildt J; Hirvonen J; Hagström J; Irjala H; Aaltonen LM; Seppänen M; Minn H
    Cancers (Basel); 2023 Aug; 15(15):. PubMed ID: 37568786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Individualized circulating tumor DNA monitoring in head and neck squamous cell carcinoma.
    Kogo R; Manako T; Iwaya T; Nishizuka S; Hiraki H; Sasaki Y; Idogawa M; Tokino T; Koide A; Komune N; Yasumatsu R; Nakagawa T
    Cancer Med; 2022 Nov; 11(21):3960-3968. PubMed ID: 35352507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumour-agnostic plasma assay for circulating tumour DNA predicts outcome in recurrent and/or metastatic squamous cell carcinoma of the head and neck treated with a PD-1 inhibitor.
    Honoré N; van der Elst A; Dietz A; van Marcke C; Helaers R; Mendola A; Dahou H; Marbaix E; Poncin R; Seront E; Schmitz S; Limaye N; Galot R; Machiels JP
    Eur J Cancer; 2023 Dec; 195():113372. PubMed ID: 37913682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating tumour DNA alterations as biomarkers for head and neck cancer: a systematic review.
    Pall AH; Jakobsen KK; Grønhøj C; von Buchwald C
    Acta Oncol; 2020 Jul; 59(7):845-850. PubMed ID: 32223478
    [No Abstract]   [Full Text] [Related]  

  • 16. A Pilot Study to Non-Invasively Track PIK3CA Mutation in Head and Neck Cancer.
    Schmidt H; Kulasinghe A; Allcock RJN; Tan LY; Mokany E; Kenny L; Punyadeera C
    Diagnostics (Basel); 2018 Nov; 8(4):. PubMed ID: 30501041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utility of plasma circulating tumor DNA and tumor DNA profiles in head and neck squamous cell carcinoma.
    Chikuie N; Urabe Y; Ueda T; Hamamoto T; Taruya T; Kono T; Yumii K; Takeno S
    Sci Rep; 2022 Jun; 12(1):9316. PubMed ID: 35661138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene Mutations in Circulating Tumour DNA as a Diagnostic and Prognostic Marker in Head and Neck Cancer-A Systematic Review.
    Hudečková M; Koucký V; Rottenberg J; Gál B
    Biomedicines; 2021 Oct; 9(11):. PubMed ID: 34829777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Longitudinal profiling of circulating tumour DNA for tracking tumour dynamics in pancreatic cancer.
    Sivapalan L; Thorn GJ; Gadaleta E; Kocher HM; Ross-Adams H; Chelala C
    BMC Cancer; 2022 Apr; 22(1):369. PubMed ID: 35392854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor-agnostic plasma assay for circulating tumor DNA detects minimal residual disease and predicts outcome in locally advanced squamous cell carcinoma of the head and neck.
    Honoré N; van Marcke C; Galot R; Helaers R; Ambroise J; van Maanen A; Mendola A; Dahou H; Marbaix E; Van Eeckhout P; Longton E; Magremanne M; Schmitz S; Limaye N; Machiels JP
    Ann Oncol; 2023 Dec; 34(12):1175-1186. PubMed ID: 37879442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.